Dapagliflozin ameliorates diabetic kidney disease by inhibiting oxidative stress and AIM2-dependent pyroptosis via SIRT1 activation
Biochemical Pharmacology · 2026-09 · 251 · 118200
DOI: 10.1016/j.bcp.2026.118200 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Pharmacology, 2026-09. Verfasst von Hao Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Clinical Pharmacy, Shenyang Pharmaceutical University, Wenhua Road 103, Shenyang 110016, China. Hauptthemen laut MEDLINE: Glucosides, Sirtuin 1, Benzhydryl Compounds, Oxidative Stress. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: Shenyang Pharmaceutical University.
Abstract (Originalsprache)
Diabetic kidney disease (DKD), a predominant microvascular complication of diabetes mellitus, still lacks curative therapies to completely halt its progressive deterioration. Our study investigated the renoprotective mechanisms of dapagliflozin (dapa) in DKD. Through bioinformatic analysis of clinical DKD datasets, preclinical in vivo and in vitro assays, we identified absent in melanoma 2 (AIM2) as a critical pyroptosis-associated gene upregulated in DKD. In silico structure-based validation revealed that dapa stably binds to the catalytic domain of silent information regulator 1 (SIRT1) via key residues GLN-361 and SER-365, suggesting its potential to modulate SIRT1 deacetylase function. Gain- and loss-of-function assays confirmed that SIRT1 is the core functional target of dapa: dapa upregulated SIRT1 protein expression to inhibit nuclear factor-κB (NF-κB) signaling, thereby blocking AIM2 inflammasome-mediated renal tubular pyroptosis and oxidative damage. These findings reveal a previously unreported mechanism by which dapa regulates SIRT1/NF-κB/AIM2 signaling to exert renoprotection, and provide promising therapeutic targets for the clinical management of DKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Clinical Pharmacy, Shenyang Pharmaceutical University, Wenhua Road 103, Shenyang 110016, China.
- School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Wenhua Road 103, Shenyang 110016, China.
- School of Clinical Pharmacy, Shenyang Pharmaceutical University, Wenhua Road 103, Shenyang 110016, China. Electronic address: kzhangchn@163.com.
- School of Clinical Pharmacy, Shenyang Pharmaceutical University, Wenhua Road 103, Shenyang 110016, China. Electronic address: wangjiahong@syphu.edu.cn.
Förderung
- Shenyang Pharmaceutical University
Zitieren
APA
Wang, H., Li, C., Wang, X., Yan, F., Li, B., Gao, J., Zhang, K., & Wang, J. (2026). Dapagliflozin ameliorates diabetic kidney disease by inhibiting oxidative stress and AIM2-dependent pyroptosis via SIRT1 activation. Biochemical Pharmacology, 251, 118200. https://doi.org/10.1016/j.bcp.2026.118200
Vancouver
Wang H, Li C, Wang X, Yan F, Li B, Gao J, et al. Dapagliflozin ameliorates diabetic kidney disease by inhibiting oxidative stress and AIM2-dependent pyroptosis via SIRT1 activation. Biochemical Pharmacology. 2026;251:118200. doi:10.1016/j.bcp.2026.118200
BibTeX
@article{Wang2026,
author = {Wang, Hao and Li, Chunliu and Wang, Xiao and Yan, Feng and Li, Bihan and Gao, Jiahui and Zhang, Kuo and Wang, Jiahong},
title = {Dapagliflozin ameliorates diabetic kidney disease by inhibiting oxidative stress and AIM2-dependent pyroptosis via SIRT1 activation},
journal = {Biochemical Pharmacology},
year = {2026},
volume = {251},
pages = {118200},
doi = {10.1016/j.bcp.2026.118200}
}
EUVIMED